Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (June 2019)
11 slides from Biocon's investor presentation, Jun 13, 2019
Slide 1: Investor Presentation cover letter to stock exchanges
<$siocon Biocon Limited 20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA 1978PLC003417 www.biocon.com June 13, 2019 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services C
Slide 2: e co ·- co
c: C7'l e 0 ...... 'l""' 0 N cu c ::::s -, 5I- tQ QJ M 'l""' ~ > ro "' u -a.. ·- 5I- tlO ro 0 -·- 0 ·-E ·- co ·- co V') 0 c -ro 0 ..c u 0 0 -(D ·- co <(
Slide 3: Biosimilars - The Next Big Global Healthcare Opportunity
L----1 Biosimilars - The Next Big Global Healthcare Opportunity High investments, quality focus and scale needed to deliver biosimilars across the world A Biosimilar Is A Biological Product A Biosimilar Has No Clinically Meaningful Differences From A Reference Product Larg~ and gen~rally Produced fr
Slide 4: Biosimilars - To deliver affordable innovation globally
L----1 ToBiosimilars- The Next Big Global Healthcare Opportunity deliver affordable innovation globally • For the treatment of severe diseases • Key to progress towards universal healthcare • To significantly lessen the financial burden of healthcare systems# • An attractive business opportunity • 1
Slide 5: Biocon Biologics - Fully Integrated Player For Biosimilars
.____I Biocon Biologics- Fully Integrated Player For Biosimilars Getting it right the first time- an early mover 1. One of the broadest pipelines 2. Many firsts to our credit .....a-··--'·-~- --· ... --~ 3. Products commercialized in U.S., Europe, Japan Biocon Malaysia: Asia's largest integrated ins
Slide 6: Biocon Biologics - Leveraging Global Trends In Healthcare
Biocon Biologics - Leveraging Global Trends In Healthcare Bringing innovation to healthcare 1. Funding & payment models 1. Drug development and manufacturing 2. Patient ecosystems 2. Digital marketing and distribution 3. Policy work ~
Slide 7: Biocon Biologics - Business Performance in FY19
L...---1 Biocon Biologics - Business Performance in FV19 A landmark year- strong realization in developed and Most of the World markets • Crossed USD 200 million revenue milestone • Revenue growth of 97% YoY • 27% of consolidated Biocon revenue FV19 vs 17% last year • Profit Before Interest and Tax
Slide 8: Biocon Biologics - What to Expect In The Next Decade?
Biocon Biologics- What to Expect In The Next Decade? Building on the current momentum • Accelerating the growth path • Ability to further differentiate and disrupt healthcare • Further strengthening the broad pipeline • Leveraging our affordable innovation model & global scale R&D Only few players m
Slide 9: Biocon Biologics - Set For Success - A Major Global Player in Biosimilars
Biocon Biologics - Set For Success - A Major Global Player in Biosimilars .....____.I A fully integrated player who gets its right the first time 1. · Well positioned to further build on our early mover advantage 2. Continued investments in R&D and capacity to build on the early success story 3. Abl
Slide 10: Questions?
Slide 11: 8 a .... fQ c
c:: 8a E 0 u ....fQ c:: 0 u .!2 ..c :: ~ ~ G 0 0 c 0